Onco-hematologia
Seguimento de 2 anos de estudo de braço único | Ciltacabtageno Autoleucel, uma terapia de células T do receptor de antígeno quimérico anticélula B de maturação, para mieloma múltiplo recorrente/refratário.
19 Jun, 2022 | 13:02hEstudo original: Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study – The Lancet (link para o resumo – $ para o texto completo)
Comentário no Twitter
In follow-up from CARTITUDE-1 trial of ciltacabtagene autoleucel in R/R MM, ORR was 97.9% and 82.5% had a stringent CR. 27-mo PFS was 54% and OS was 70.4% https://t.co/cnpzkg5yKM
— NatureRevClinOncol (@NatRevClinOncol) June 9, 2022
Análise primária da coorte CAPTIVATE FD | Ibrutinibe de duração fixa com venetoclax para tratamento de primeira linha da leucemia linfoide crônica.
16 Jun, 2022 | 11:57hClassificação de consenso internacional de neoplasias linfoides maduras.
16 Jun, 2022 | 11:56hRastreamento baseado em ressonância magnética cardíaca para sarcoidose cardíaca em pacientes com bloqueio atrioventricular que necessitam de marca-passo temporário.
14 Jun, 2022 | 13:35hComentário convidado: Managing Patients With Advanced Atrioventricular Block: The Essential Role of Cardiovascular Magnetic Resonance Imaging for Timely and Accurate Diagnosis – Journal of the American Heart Association
Recomendações ESTRO ACROP e SIOPE para irradiação mieloablativa corporal total em crianças.
14 Jun, 2022 | 12:48hRevisão | Urgências e emergências oncológicas.
13 Jun, 2022 | 15:05hOncologic emergencies and urgencies: A comprehensive review – CA: A Cancer Journal for Clinicians
Comentário no Twitter
🎯Just in time for #ASCO22 | Oncologic emergencies and urgencies: A comprehensive review https://t.co/HyZmI37tr5 @BEGouldRothberg @YaleCancer @KeithDelman
CC: @OncoAlert pic.twitter.com/57tqiLXijN— CA: A Cancer Journal for Clinicians (@CAonline) June 2, 2022
#ASCO22 – Estudo randomizado | Ibrutinibe com bendamustina e rituximabe no linfoma de células do manto.
13 Jun, 2022 | 14:43hIbrutinib plus Bendamustine and Rituximab in Untreated Mantle-Cell Lymphoma – New England Journal of Medicine (link para o resumo – $ para o texto completo)
Comunicado de imprensa: Ibrutinib with chemoimmunotherapy improved progression-free survival for newly diagnosed mantle cell lymphoma patients – BTK inhibitor as front-line option for MCL – University of Texas M. D. Anderson Cancer Center
#ASCO22 – Estudo de braço único fases 1-2 | Teclistamabe no mieloma múltiplo recidivante ou refratário.
13 Jun, 2022 | 14:38hTeclistamab in Relapsed or Refractory Multiple Myeloma – New England Journal of Medicine
Comentário no Twitter
MajesTEC-1: Teclistamab resulted in a high incidence of deep and durable response in patients with triple-class–exposed relapsed or refractory multiple myeloma. #ASCO22 https://t.co/Nanjob1q7p pic.twitter.com/oqfaiu8MOx
— NEJM (@NEJM) June 5, 2022
#ASCO22 – Estudo randomizado | Terapia tripla, transplante e manutenção até a progressão no mieloma.
13 Jun, 2022 | 14:37hTriplet Therapy, Transplantation, and Maintenance until Progression in Myeloma – New England Journal of Medicine (link para o resumo – $ para o texto completo)
Comunicado de imprensa: Improved progression-free survival in multiple myeloma patients following three-drug therapy with autologous stem cell transplant – Dana-Farber Cancer Institute
Comentário no Twitter
DETERMINATION: Among adults with multiple myeloma, continuous lenalidomide maintenance therapy after triplet therapy (RVD, plus ASCT) associated with longer PFS than triplet therapy alone. #ASCO22 https://t.co/YhKgjc1Enz pic.twitter.com/cU8nefokZo
— NEJM (@NEJM) June 5, 2022
Estudo de coorte | Risco de câncer hematológico em pacientes com prurido indiferenciado.
31 Mai, 2022 | 11:47hRisk of Hematologic Cancer in Patients With Undifferentiated Pruritus – JAMA Dermatology (link para o resumo – $ para o texto completo)
Comentário: Undifferentiated Pruritus Associated with Increased Risk of Hematologic Cancer – HCP Live